Literature DB >> 24206590

SFPO and ESOP recommendations for the practical stability of anticancer drugs: an update.

J Vigneron1, A Astier, R Trittler, J D Hecq, M Daouphars, I Larsson, B Pourroy, F Pinguet.   

Abstract

The recommendations for the practical stability of anticancer drugs published in 2010 by the French Society of Hospital Pharmacists (SFPO) and the European Society of Oncology Pharmacists (ESOP) have been updated. Ten new molecules have been included (asparaginase, azacitidine, bevacizumab, clofarabine, eribuline mesylate, folinate sodium, levofolinate calcium, nelarabine, rituximab, temsirolimus).
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anticancer drugs; Anticancéreux; Anticorps monoclonaux; Dose banding; Monoclonal antibodies; Stabilis(®); Stability; Stabilité

Mesh：

Substances：

Year:  2013        PMID： 24206590     DOI： 10.1016/j.pharma.2013.06.002

Source DB:  PubMed          Journal:  Ann Pharm Fr        ISSN： 0003-4509


  5 in total

1.  Do bevacizumab solutions interact with silicone or polyurethane catheters during an infusion through implantable venous access ports?

Authors:  Nicolas Tokhadzé; Philip Chennell; Régis Cueff; Valérie Sautou
Journal:  J R Soc Interface       Date:  2019-09-25       Impact factor: 4.118

2.  Exploratory analysis for the implementation of antineoplastic logarithmic dose banding.

Authors:  A Albert-Marí; S Valero-García; V Fornés-Ferrer; J L Poveda-Andrés
Journal:  Int J Clin Pharm       Date:  2018-08-10

3.  The impact of logarithmic dose banding of anticancer drugs on pharmacy compounding efficiency at Ghent University Hospital.

Authors:  Barbara Claus; Kaat De Pourcq; Nele Clottens; Vibeke Kruse; Paul Gemmel; Johan Vandenbroucke
Journal:  Eur J Hosp Pharm       Date:  2017-03-04

4.  A Cost Saving and Waste Minimization Study About Handling of the Antineoplastic Agents.

Authors:  Metin Deniz Karakoç
Journal:  Turk J Pharm Sci       Date:  2017-11-20

5.  The physical and chemical stability of cisplatin (Teva) in concentrate and diluted in sodium chloride 0.9%.

Authors:  Agnieszka Karbownik; Edyta Szałek; Hanna Urjasz; Aleksandra Głęboka; Emilia Mierzwa; Edmund Grześkowiak
Journal:  Contemp Oncol (Pozn)       Date:  2012-11-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.